LPCN News and Press, Lipocine Inc. From 01/25/21

Lipocine (LPCN) slumped 11.8% in after hours trade after planning to offer shares for sale in an underwritten public offering; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms have not yet been disclosed.Proceeds to be used for g...

Lipocine Announces Launch Of Public Offering Of Common Stock PR Newswire SALT LAKE CITY , Jan. 25, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that...

Vinco Ventures (BBIG) +265%.Genetic Technologies (GENE) +79% as COVID-19 risk test further enhances predictive capabilities.Celsion (CLSN) +65%.Addex Therapeutics (ADXN) +64% as ADX71149 receives IND approval to start a phase 2a clinical study in Epilepsy.INmune Bio (INMB) +39% ...

Will These 5 Biotech Penny Stocks Rally Under a New President? As the biotech industry continues its surge, many investors wonder which biotech penny stocks could be worth watching right now. This is a tough question to answer in only a few sentences, as there are plenty of implicat...

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications PR Newswire SALT LAKE CITY , Jan. 14, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endoc...

Clinical-stage biopharmaceutical company Lipocine (LPCN) announces that its treatment for biopsy-confirmed non-cirrhotic non-alcoholic steatohepatitis ((NASH)) in male patients, showed statistically significant reduction in liver fat compared to placebo as part of a phase 2 trial.In...

La Jolla Pharmaceutical (LJPC) +62% on exclusive licensing agreement with PAIONVOXX International (VOXX) +56% after posting strong sales growth.T2 Biosystems (TTOO) +33% after the company says its T2SARS-CoV-2 Panel is capable of detecting multiple variants of the COVID-19 viru...

Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects Conference Call Scheduled for 8:30 a.m. ET today -- Both LPCN 1144 treatment arms met the primary endpoint with statistical significance -- Statistical...

Lipocine to Present at the H.C. Wainwright BioConnect 2021 Conference PR Newswire SALT LAKE CITY , Jan. 4, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced t...

Click here to read the previous top NASDAQ pharma stocks article. 2020 wasn’t without challenges for the pharmaceutical market, which like other sectors is bound to face lasting impacts from the COVID-19 pandemic. That being said, the major underlying drivers for ...